S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

$9.04
+0.19 (+2.15%)
(As of 03/28/2024 ET)
Today's Range
$8.83
$9.24
50-Day Range
$8.48
$10.21
52-Week Range
$5.57
$11.26
Volume
868,997 shs
Average Volume
548,542 shs
Market Capitalization
$493.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.21

Marinus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
134.7% Upside
$21.21 Price Target
Short Interest
Bearish
6.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.55
Upright™ Environmental Score
News Sentiment
0.21mentions of Marinus Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.44) to ($1.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

264th out of 938 stocks

Pharmaceutical Preparations Industry

123rd out of 437 stocks

MRNS stock logo

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Stock Price History

MRNS Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
MRNS Jul 2024 16.000 call
MRNS Mar 2024 7.000 put
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Marinus Pharmaceuticals: Q4 Earnings Snapshot
Q4 2023 Marinus Pharmaceuticals Inc Earnings Call
Marinus Pharma's Earnings Outlook
MRNS Mar 2024 13.000 call
MRNS Mar 2024 10.000 put
See More Headlines
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNS
Employees
165
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.21
High Stock Price Target
$28.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+134.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-141,400,000.00
Net Margins
-456.31%
Pretax Margin
-461.27%

Debt

Sales & Book Value

Annual Sales
$30.99 million
Book Value
$0.31 per share

Miscellaneous

Free Float
51,987,000
Market Cap
$493.95 million
Optionable
Optionable
Beta
0.93
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Scott N. Braunstein M.D. (Age 61)
    CEO, President & Chairman
    Comp: $919.29k
  • Mr. Steven E. Pfanstiel C.M.A. (Age 50)
    M.B.A., COO, CFO & Treasurer
    Comp: $580.35k
  • Dr. Joseph Hulihan M.D. (Age 68)
    Chief Medical Officer
    Comp: $639.51k
  • Dr. Alex Aimetti Ph.D.
    Chief Scientific Officer
  • Ms. Sonya Weigle
    Senior VP of Investor Relations, Human Resources & Corporate Affairs
  • Ms. Martha E. Manning Esq. (Age 69)
    J. D., Senior VP, General Counsel & Secretary
  • Molly Cameron
    Director of Corporate Communications & Investor Relations
  • Dr. Kimberly A. McCormick Pharm.D.
    Chief Regulatory & Quality Assurance Officer
  • Mr. Thomas J. Lyons
    Chief Business Officer
  • Ms. Christina Shafer (Age 48)
    Chief Commercial Officer

MRNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price target for 2024?

7 brokers have issued 12-month target prices for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $9.00 to $28.00. On average, they anticipate the company's share price to reach $21.21 in the next year. This suggests a possible upside of 134.7% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2024?

Marinus Pharmaceuticals' stock was trading at $10.87 at the start of the year. Since then, MRNS stock has decreased by 16.8% and is now trading at $9.04.
View the best growth stocks for 2024 here
.

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MRNS earnings forecast
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its quarterly earnings data on Tuesday, March, 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.10. The biopharmaceutical company earned $7.19 million during the quarter, compared to analysts' expectations of $7.78 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 269.75% and a negative net margin of 456.31%. During the same quarter last year, the firm posted ($0.76) earnings per share.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did Marinus Pharmaceuticals' stock split?

Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (7.03%), Jennison Associates LLC (5.42%), Vanguard Group Inc. (4.90%), Vanguard Group Inc. (4.89%), Opaleye Management Inc. (1.03%) and abrdn plc (1.01%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel.
View institutional ownership trends
.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners